Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector

By HEOR Staff Writer

April 28, 2026

In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Marking under the EU Medical Device Regulation and has...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
TikTok Opioid Overdose Forecasting is gaining attention as a powerful new approach to public health surveillance. A new study shows that comments on opioid-related TikTok videos can significantly improve predictions of synthetic opioid deaths, reducing forecasting errors by up to 37% compared wit...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers

By HEOR Staff Writer

April 27, 2026

Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
The launch of AVIBELA marks a significant milestone for hormonal IUD South Africa, introducing the country’s first generic levonorgestrel 52 mg intrauterine device. Developed by Medicines360 and commercialized in partnership with Pharma Dynamics, AVIBELA is more than 99% effective at preventing p...
Search By Category

Latest

Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector

By HEOR Staff Writer

April 28, 2026

In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...

Latest

Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Marking under the EU Medical Device Regulation and has...

Latest

TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
TikTok Opioid Overdose Forecasting is gaining attention as a powerful new approach to public health surveillance. A new study shows that comments on opioid-related TikTok videos can significantly improve predictions of synthetic opioid deaths, reducing forecasting errors by up to 37% compared wit...

Latest

Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...

Global Updates

Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...

Global Updates

Regulatory Divergence in PSMA Targeted Therapy: Implications for European Market Access

By HEOR Staff Writer

April 27, 2026

Novartis withdrew its European Medicines Agency (EMA) application to expand the indication for Pluvicto® (lutetium (177Lu) vipivotide tetraxetan). The company sought to include adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have not yet received chem...

Global Updates

Advancing Multicenter AKI Prediction: Benefits of Collaborative Models Over Localized Approaches

By HEOR Staff Writer

April 24, 2026

New evidence demonstrates that multicenter AKI prediction models significantly outperform locally trained single-center models for forecasting postoperative acute kidney injury (AKI) after cardiac surgery. The study, published in npj Digital Medicine, analyzed 43,926 cardiac surgery c...

Global Updates

Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovascular Disease in Europe

By João L. Carapinha

April 23, 2026

Europe loses approximately €240 billion every year because of the interconnected burdens of obesity diabetes cardiovascular disease (EFPIA Guest Blog). Fragmented healthcare systems that treat late-stage complications instead of preventing disease progression are largely responsible for this mass...

Europe

Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector

By HEOR Staff Writer

April 28, 2026

In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Marking under the EU Medical Device Regulation and has...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
TikTok Opioid Overdose Forecasting is gaining attention as a powerful new approach to public health surveillance. A new study shows that comments on opioid-related TikTok videos can significantly improve predictions of synthetic opioid deaths, reducing forecasting errors by up to 37% compared wit...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...

North America

TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
TikTok Opioid Overdose Forecasting is gaining attention as a powerful new approach to public health surveillance. A new study shows that comments on opioid-related TikTok videos can significantly improve predictions of synthetic opioid deaths, reducing forecasting errors by up to 37% compared wit...
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Market Access

By HEOR Staff Writer

April 27, 2026

Novartis withdrew its European Medicines Agency (EMA) application to expand the indication for Pluvicto® (lutetium (177Lu) vipivotide tetraxetan). The company sought to include adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have not yet received chem...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Terminal complement inhibition with Ultomiris (ravulizumab) delivered a statistically significant and clinically meaningful reduction in proteinuria at week 34 in adults with immunoglobulin A nephropathy (IgAN) at high risk of progression. According to the prespecified interim analysis of the Pha...

Sub-Saharan Africa

Medical Device Innovation South Africa: Breaking Down Systemic Barriers

By HEOR Staff Writer

April 27, 2026

Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
The launch of AVIBELA marks a significant milestone for hormonal IUD South Africa, introducing the country’s first generic levonorgestrel 52 mg intrauterine device. Developed by Medicines360 and commercialized in partnership with Pharma Dynamics, AVIBELA is more than 99% effective at preventing p...
HIV Prevention Partnerships: Expanding Access to Lenacapavir for Global Impact

By João L. Carapinha

April 17, 2026

HIV Prevention Partnerships between PEPFAR, The Global Fund, and Gilead Sciences are accelerating access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) in high-burden countries. Unprecedented Speed to Sub-Saharan Africa This additional i...
Expansion of Community Health Programs by Novartis to Tackle Global Health Disparities

By João L. Carapinha

April 9, 2026

Novartis’ ambitious scale-up of community health programs aims to close critical gaps in cardiovascular and cancer care. Announced on April 9, 2026, the initiative will expand these community health programs from 11 to more than 30 countries by 2030, including five major U.S. cities, with a stron...